I Reunión Post-European Headache Federation: Revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Introduction. After the European Headache Federation (EHF) Congress, renowned Spanish neurologists specialised in migraine presented the most significant latest developments in research in this field at the Post-EHF Meeting. Development. The main data presented concerning the treatment of chronic and episodic migraine were addressed, with attention paid more specifically to those related to preventive treatments and real-life experience in the management of the disease. An important review was carried out of the new therapeutic targets and the possibilities they offer in terms of understanding the pathophysiology of migraine and its treatment. An update was also presented of the latest developments in the treatment of migraine with fremanezumab, a monoclonal antibody recently authorised by the European Medicines Agency. Participants were also given an update on the latest developments in basic research on the pathology, as well as an overview of the symptoms of migraine and COVID-19. Finally, the repercussions of migraine in terms of its burden on the care and economic resources of the health system were addressed, along with its impact on society. Conclusions. The meeting summarised the content presented at the 14th EHF Congress, which took place in late June/early July 2020.
| Bidragets oversatte titel | 1st Post-European Headache Federation Meeting: A review of the latest developments presented at the 2020 European Headache Federation Congress |
|---|---|
| Originalsprog | Spansk |
| Tidsskrift | Revista de Neurologia |
| Vol/bind | 72 |
| Udgave nummer | S2 |
| Sider (fra-til) | S1-S19 |
| ISSN | 0210-0010 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
J.M.L. has received honoraria and research grants from Allergan, Amgen, Bial, Boehringher, Chiesi, ElectroCore, Eli Lily, Medtronic, Merck, Novartis, Otsuka, Prim, Roche, Teva and UCB. M.A. has received honoraria for services as a consultant, speaker or adviser from Abbvie, Allergan, Amgen, Alder, Biohaven, Eli Lilly, Lundbeck, Novartis and Teva; as principal investigator from Alder, Amgen, Allergan, Eli Lilly, Lundbeck, Novartis and Teva; is associate editor of the journals Cephalalgia and Journal of Headache and Pain; and is president of the International Headache Society. R.B. has received honoraria from Abbvie, Allergan, Chiesi, Novartis, Teva and Eli Lilly. S.D.I. has received honoraria from Allergan, Almirall, Bial, Chiesi, Fundació Universitat-Empresa de València, Kern Pharma, Eli Lilly, Lundbeck, MSD, Novartis and Teva. D.E. has received honoraria for speaking at training activities organised by Allergan, Chiesi, Exeltis, Eli Lilly, Novartis and Teva. A.L.G. has received honoraria for speaking at conferences or for consultancy services from Allergan, Exeltis, Eli Lilly, Novartis and Teva. A.G. has received honoraria for consultancy services from Eli Lilly, and as a speaker and moderator at training courses and symposia for Allergan, Novartis and Teva. D.H.L. has received honoraria and research grants from Allergan, Amgen, Eli Lilly, Hormosan, Medtronic, Merck, Novartis and Teva. M.H.V. has received honoraria for consultancy services from Allergan, Eli Lilly and Novartis; for presentations, courses, seminars, editorial activities or the preparation of training materials from Almirall, Allergan, Chiesi, Eisai, Kern Pharma, Teva and Zambón; research grants from Allergan; and compensation for participating in clinical trials and studies from Amgen, Eli Lilly and Novartis. J.P. has received honoraria for participating in symposia or consultancy activities from Allergan, Amgen, Biohaven, Eli Lilly, Novartis and Teva. P.P.R. has received honoraria for advisory services and as a speaker from Abbvie, Almirall, Amgen, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received grants from Novartis, Teva, Fundación La Caixa, EraNet Neuron, Instituto de Salud Carlos III, Migraine Research Foundation, MINECO, Mutual Médica, PERIS, FEDER RISC3CAT and AGAUR. She is associate editor of the journals Cephalgia, Headache, Neurología and Revista de Neurología, as well as a member of the panel of
Publisher Copyright:
© 2021 Revista de Neurologia. All rights reserved.
- Chronic migraine, EHF, Episodic migraine, Fremanezumab, Headache, Migraine, Post-EHF
Forskningsområder
ID: 300992237